Compared to DPP-4 inhibitors, GLP-1 receptor agonists have the potential for more robust A1C reductions (0.5% to 2.0%) and weight loss
The original Ultherapy proved that we could lift the face without a scalpel
They are used to treat heart conditions such as High blood pressure (Hypertension), Angina (Chest pain), Heart failure, and Arrhythmias, as well as other conditions like Essential tremor, Migraines, and Glaucoma
Exposure to light and oxygen degrades copper peptides, making them less effective
Typical PA requirements include: Confirmed diagnosis of type 2 diabetes or obesity Documented BMI (often 30 or 27 with comorbidities) Failed trials of other medications Lifestyle modification attempts Recent A1C lab values (for diabetes) Documentation Must Include Height and weight with calculated BMI Diagnosis supporting medical necessity Treatment plan Follow-up and monitoring plan Compliance & Audit Risk GLP-1 medications are a high-risk audit target due to: Rapid growth in utilization High drug cost Off-label prescribing Weight-loss demand Common audit issues: Incorrect diagnosis codes Missing BMI documentation Lack of medical necessity Billing weight-loss drugs to Medicare Inappropriate use of unclassified J-codes Medicare Coverage Rules Medicare Part D generally does not cover weight-loss drugs , even if FDA-approved for obesity
